Previous 10 | Next 10 |
Applied Molecular Transport (AMTI) has priced its public offering of 2.5M common shares at $42.00/share, for expected gross proceeds of $105M.Underwriters' over-allotment is an additional 375K shares. BofA Securities, Jefferies, and SVB Leerink are acting as joint book-running managers.Closin...
SOUTH SAN FRANCISCO, Calif., March 31, 2021 (GLOBE NEWSWIRE) -- Applied Molecular Transport Inc. (Nasdaq: AMTI) (AMT), a clinical-stage biopharmaceutical company, today announced the pricing of an underwritten public offering of 2,500,000 shares of its common stock at a public offering pric...
Applied Molecular Transport (AMTI) commenced an underwritten public offering of 2.5M shares; underwriters granted 30-day option to purchase up to an additional 375K shares.Offer size, terms not yet disclosed. For further details see: Applied Molecular Transport proposes 2.5M ...
SOUTH SAN FRANCISCO, Calif., March 29, 2021 (GLOBE NEWSWIRE) -- Applied Molecular Transport Inc. (Nasdaq: AMTI) (AMT), a clinical-stage biopharmaceutical company, today announced that it has commenced an underwritten public offering of 2,500,000 shares of its common stock. All of the shares...
Applied Molecular Transport (AMTI): FY GAAP EPS of -$2.91 beats by $0.38.As of December 31, 2020, cash, cash equivalents, and investments were $129.9 million.Press Release For further details see: Applied Molecular Transport EPS beats by $0.38
Successfully initiated four planned Phase 2 trials for oral AMT-101 with enrollment ongoing Company on track to announce oral AMT-101 top-line data readouts from the four Phase 2 trials from its comprehensive clinical program, in multiple ulcerative colitis populations and rheum...
SOUTH SAN FRANCISCO, Calif., March 09, 2021 (GLOBE NEWSWIRE) -- Applied Molecular Transport Inc. (Nasdaq: AMTI) (AMT), a clinical-stage biopharmaceutical company, today announced that Tahir Mahmood, Ph.D., chief executive officer and co-founder, will participate in a fireside chat during th...
Applied Molecular Transport (AMTI) announces that the first patient has been dosed in its Phase 1a clinical trial of oral AMT-126, a novel, gastrointestinal ((GI))-selective oral fusion of human interleukin-22 ((hIL-22)).The company expects complete data from its oral AMT-126 Phase 1a/b ...
Company expands pipeline with second clinical program, AMT-126, an oral IL-22 fusion biologic therapy for diseases associated with intestinal epithelial barrier defects IL-22 deficiency implicated in broad range of gastrointestinal-focused and peripheral diseases ranging from ul...
The following slide deck was published by Applied Molecular Transport Inc. in conjunction with this event. For further details see: Applied Molecular Transport (AMTI) Investor Presentation - Slideshow
News, Short Squeeze, Breakout and More Instantly...
Applied Molecular Transport Inc. Company Name:
AMTI Stock Symbol:
NASDAQ Market:
Applied Molecular Transport Inc. Website:
Combined company operating as Cyclo Therapeutics with primary focus on advancing Trappsol ® Cyclo™ for the treatment of Niemann-Pick Disease Type C1 (NPC1) Cash runway extended into 2H 2024 with approximately $11.0 million cash on hand to fund operations Cyclo ...
Company Entered into Definitive Merger Agreement with Cyclo Therapeutics Cash and Cash Equivalents of $18.1 million, as of September 30, 2023 SOUTH SAN FRANCISCO, Calif., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Applied Molecular Transport Inc. (Nasdaq: AMTI) (AMT), a biopharmaceut...
CGG ADR (CGGYY) is expected to report for quarter end 2023-09-30 ATI Physical Therapy Inc. Class A (ATIP) is expected to report $-4.08 for Q3 2023 Riot Platforms Inc. (RIOT) is expected to report $-0.29 for Q3 2023 Bain Capital Specialty Finance Inc. (BCSF) is expected to report $0.57...